A Randomized, Phase III, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)
Categories (click each to see list of all clinical trials associated with that category): Melanoma (ONC), Ophthalmology (ONC)
Current Status: Open
Phase: III (Cancer Control)
Principal Investigator: Rishi, Pukhraj
Contact Information:
Ashley Reid
asreid@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT07015190?term=NCT07015190&rank=1#participation-criteria
Summary
To demonstrate that the proportion of subjects with vision loss is lower for subjects in the Treatment Arm vs the Control Arm; To demonstrate the ability to salvage the eye and prevent enucleation in the Treatment Arm